8-K Filing

CVS HEALTH CORP CIK: 64803

Filing Information

Form Type	8-K
Accession Number	`0000064803-23-000021`
Period End Date	20221231
Filing Date	20230525
Fiscal Year	N/A
Fiscal Period	N/A
XBRL Instance	cvs-20230525_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 107 Income Statement 97 Cash Flow Statement 142 Stockholders Equity 39 Comprehensive Income 30

Balance Sheet 107 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.41B	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	100,000.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.85B	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	100,000.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$12.95B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Investments	`ShortTermInvestments`	$3.12B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Investments	`ShortTermInvestments`	$2.78B	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$27.28B	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$24.43B	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$19.09B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Inventories	`InventoryNet`	$17.76B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	3.20B	shares	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$908.00M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	3.20B	shares	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	-	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	1.76B	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$2.64B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$5.32B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	1.74B	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.30B	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.32B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$60.03B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$65.63B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockShares`	458.00M	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockShares`	422.00M	shares	Point-in-time
Long-term investments	`LongTermInvestments`	$23.02B	USD	Point-in-time
Long-term investments	`LongTermInvestments`	$21.10B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$12.90B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$12.87B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$17.87B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$19.12B	USD	Point-in-time
Goodwill	`Goodwill`	$79.12B	USD	Point-in-time
Goodwill	`Goodwill`	$79.55B	USD	Point-in-time
Goodwill	`Goodwill`	$78.15B	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$24.80B	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$29.05B	USD	Point-in-time
Separate accounts assets	`SeparateAccountAssets`	$3.23B	USD	Point-in-time
Separate accounts assets	`SeparateAccountAssets`	$5.09B	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$4.71B	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$4.62B	USD	Point-in-time
Total assets	`Assets`	$228.28B	USD	Point-in-time
Total assets	`Assets`	$233.05B	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	$12.54B	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	$14.84B	USD	Point-in-time
Pharmacy claims and discounts payable	`PharmacyClaimsAndDiscountsPayableCurrent`	$17.33B	USD	Point-in-time
Pharmacy claims and discounts payable	`PharmacyClaimsAndDiscountsPayableCurrent`	$19.42B	USD	Point-in-time
Health care costs payable	`LiabilityForClaimsAndClaimsAdjustmentExpense`	$8.68B	USD	Point-in-time
Health care costs payable	`LiabilityForClaimsAndClaimsAdjustmentExpense`	$10.14B	USD	Point-in-time
Policyholders funds	`OtherPolicyholderFunds`	$1.50B	USD	Point-in-time
Policyholders funds	`OtherPolicyholderFunds`	$4.30B	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$17.67B	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$18.75B	USD	Point-in-time
Other insurance liabilities	`OtherInsuranceLiabilitiesCurrent`	$1.09B	USD	Point-in-time
Other insurance liabilities	`OtherInsuranceLiabilitiesCurrent`	$1.34B	USD	Point-in-time
Current portion of operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.68B	USD	Point-in-time
Current portion of operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.65B	USD	Point-in-time
Current portion of long-term debt	`LongTermDebtAndCapitalLeaseObligationsCurrent`	$1.78B	USD	Point-in-time
Current portion of long-term debt	`LongTermDebtAndCapitalLeaseObligationsCurrent`	$4.21B	USD	Point-in-time
Liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$228.00M	USD	Point-in-time
Liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$67.72B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$69.42B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$18.18B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$16.80B	USD	Point-in-time
Long-term debt (1)	`LongTermDebtAndCapitalLeaseObligations`	$50.48B	USD	Point-in-time
Long-term debt (1)	`LongTermDebtAndCapitalLeaseObligations`	$51.97B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$6.12B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$4.02B	USD	Point-in-time
Separate accounts liabilities	`SeparateAccountsLiability`	$4.88B	USD	Point-in-time
Separate accounts liabilities	`SeparateAccountsLiability`	$3.23B	USD	Point-in-time
Separate accounts liabilities	`SeparateAccountsLiability`	$5.09B	USD	Point-in-time
Other long-term insurance liabilities	`OtherInsuranceLiabilitiesNoncurrent`	$5.83B	USD	Point-in-time
Other long-term insurance liabilities	`OtherInsuranceLiabilitiesNoncurrent`	$7.24B	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.91B	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$6.73B	USD	Point-in-time
Total liabilities	`Liabilities`	$156.51B	USD	Point-in-time
Total liabilities	`Liabilities`	$158.21B	USD	Point-in-time
Commitments and contingencies (Note 17)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 17)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital surplus	`CommonStocksIncludingAdditionalPaidInCapital`	$48.19B	USD	Point-in-time
Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital surplus	`CommonStocksIncludingAdditionalPaidInCapital`	$47.38B	USD	Point-in-time
Treasury stock, at cost: 458 and 422 shares at December 31, 2022 and 2021	`TreasuryStockValue`	$31.86B	USD	Point-in-time
Treasury stock, at cost: 458 and 422 shares at December 31, 2022 and 2021	`TreasuryStockValue`	$28.17B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$55.00B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$56.40B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.26B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$334.00M	USD	Point-in-time
Total CVS Health shareholders equity	`StockholdersEquity`	$71.47B	USD	Point-in-time
Total CVS Health shareholders equity	`StockholdersEquity`	$74.53B	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$300.00M	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$306.00M	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$69.70B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$64.17B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$74.84B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$71.77B	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$228.28B	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$233.05B	USD	Point-in-time

Income Statement 97 line items

Line Item	Tag	Value	Unit	Period
Premiums	`PremiumsEarnedNet`	$69.36B	USD	Annual
Premiums	`PremiumsEarnedNet`	$85.33B	USD	Annual
Premiums	`PremiumsEarnedNet`	$76.13B	USD	Annual
Net investment income	`NetInvestmentIncome`	$838.00M	USD	Annual
Net investment income	`NetInvestmentIncome`	$1.20B	USD	Annual
Net investment income	`NetInvestmentIncome`	$798.00M	USD	Annual
Total revenues	`Revenues`	$268.71B	USD	Annual
Total revenues	`Revenues`	$292.11B	USD	Annual
Total revenues	`Revenues`	$322.47B	USD	Annual
Cost of products sold	`CostOfGoodsAndServicesSold`	$175.80B	USD	Annual
Cost of products sold	`CostOfGoodsAndServicesSold`	$196.89B	USD	Annual
Cost of products sold	`CostOfGoodsAndServicesSold`	$163.98B	USD	Annual
Benefit costs	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$55.68B	USD	Annual
Benefit costs	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$64.19B	USD	Annual
Benefit costs	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$71.07B	USD	Annual
Opioid litigation charges	`GainLossRelatedToLitigationSettlement`	-	USD	Annual
Opioid litigation charges	`GainLossRelatedToLitigationSettlement`	-	USD	Annual
Opioid litigation charges	`GainLossRelatedToLitigationSettlement`	$-5.80B	USD	Annual
Loss on assets held for sale	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	Annual
Loss on assets held for sale	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	Annual
Loss on assets held for sale	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$2.53B	USD	Annual
Store impairments	`StoreImpairmentCharges`	-	USD	Annual
Store impairments	`StoreImpairmentCharges`	-	USD	Annual
Store impairments	`StoreImpairmentCharges`	$1.36B	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	$431.00M	USD	Annual
Operating expenses	`OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement`	$35.13B	USD	Annual
Operating expenses	`OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement`	$38.21B	USD	Annual
Operating expenses	`OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement`	$37.02B	USD	Annual
Total operating costs	`CostsAndExpenses`	$278.80B	USD	Annual
Total operating costs	`CostsAndExpenses`	$254.79B	USD	Annual
Total operating costs	`CostsAndExpenses`	$314.51B	USD	Annual
Operating income	`OperatingIncomeLoss`	$13.91B	USD	Annual
Operating income	`OperatingIncomeLoss`	$7.95B	USD	Annual
Operating income	`OperatingIncomeLoss`	$13.31B	USD	Annual
Interest expense	`InterestExpense`	$2.29B	USD	Annual
Interest expense	`InterestExpense`	$2.50B	USD	Annual
Interest expense	`InterestExpense`	$2.91B	USD	Annual
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-363.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-89.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-766.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-1.44B	USD	Annual
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-674.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-452.00M	USD	Annual
Other income	`OtherNonoperatingIncomeExpense`	$169.00M	USD	Annual
Other income	`OtherNonoperatingIncomeExpense`	$182.00M	USD	Annual
Other income	`OtherNonoperatingIncomeExpense`	$206.00M	USD	Annual
Income before income tax provision	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$10.54B	USD	Annual
Income before income tax provision	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.84B	USD	Annual
Income before income tax provision	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$9.77B	USD	Annual
Income tax provision	`IncomeTaxExpenseBenefit`	$2.55B	USD	Annual
Income tax provision	`IncomeTaxExpenseBenefit`	$2.57B	USD	Annual
Income tax provision	`IncomeTaxExpenseBenefit`	$1.51B	USD	Annual
Income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$7.20B	USD	Annual
Income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$7.99B	USD	Annual
Income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$4.33B	USD	Annual
Loss from discontinued operations, net of tax	`IncomeLossFromDiscontinuedOperationsNetOfTax`	-	USD	Annual
Loss from discontinued operations, net of tax	`IncomeLossFromDiscontinuedOperationsNetOfTax`	$-9.00M	USD	Annual
Loss from discontinued operations, net of tax	`IncomeLossFromDiscontinuedOperationsNetOfTax`	-	USD	Annual
Net income	`ProfitLoss`	$7.99B	USD	Annual
Net income	`ProfitLoss`	$4.33B	USD	Annual
Net income	`ProfitLoss`	$7.19B	USD	Annual
Net (income) loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-12.00M	USD	Annual
Net (income) loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$13.00M	USD	Annual
Net (income) loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$16.00M	USD	Annual
Net income attributable to CVS Health	`NetIncomeLoss`	$4.31B	USD	Annual
Net income attributable to CVS Health	`NetIncomeLoss`	$7.18B	USD	Annual
Net income attributable to CVS Health	`NetIncomeLoss`	$8.00B	USD	Annual
Income from continuing operations attributable to CVS Health (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$5.49	USD	Annual
Income from continuing operations attributable to CVS Health (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$6.07	USD	Annual
Income from continuing operations attributable to CVS Health (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$3.29	USD	Annual
Loss from discontinued operations attributable to CVS Health (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	-	USD	Annual
Loss from discontinued operations attributable to CVS Health (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$-0.01	USD	Annual
Loss from discontinued operations attributable to CVS Health (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	-	USD	Annual
Net income attributable to CVS Health (in dollars per share)	`EarningsPerShareBasic`	$6.07	USD	Annual
Net income attributable to CVS Health (in dollars per share)	`EarningsPerShareBasic`	$3.29	USD	Annual
Net income attributable to CVS Health (in dollars per share)	`EarningsPerShareBasic`	$5.48	USD	Annual
Weighted average basic shares outstanding (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.32B	shares	Annual
Weighted average basic shares outstanding (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.31B	shares	Annual
Weighted average basic shares outstanding (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.31B	shares	Annual
Income from continuing operations attributable to CVS Health (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$6.02	USD	Annual
Income from continuing operations attributable to CVS Health (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$3.26	USD	Annual
Income from continuing operations attributable to CVS Health (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$5.47	USD	Annual
Loss from discontinued operations attributable to CVS Health (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare`	-	USD	Annual
Loss from discontinued operations attributable to CVS Health (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare`	-	USD	Annual
Loss from discontinued operations attributable to CVS Health (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare`	$-0.01	USD	Annual
Net income attributable to CVS Health (in dollars per share)	`EarningsPerShareDiluted`	$6.02	USD	Annual
Net income attributable to CVS Health (in dollars per share)	`EarningsPerShareDiluted`	$3.26	USD	Annual
Net income attributable to CVS Health (in dollars per share)	`EarningsPerShareDiluted`	$5.46	USD	Annual
Weighted average diluted shares outstanding (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.33B	shares	Annual
Weighted average diluted shares outstanding (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.31B	shares	Annual
Weighted average diluted shares outstanding (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.32B	shares	Annual
Dividends declared per share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.00	USD	Annual
Dividends declared per share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.20	USD	Annual
Dividends declared per share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.00	USD	Annual

Cash Flow Statement 142 line items

Line Item	Tag	Value	Unit	Period
Cash receipts from customers	`ProceedsFromCustomers`	$264.33B	USD	Annual
Cash receipts from customers	`ProceedsFromCustomers`	$284.22B	USD	Annual
Cash receipts from customers	`ProceedsFromCustomers`	$313.66B	USD	Annual
Cash paid for inventory and prescriptions dispensed by retail network pharmacies	`PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies`	$158.64B	USD	Annual
Cash paid for inventory and prescriptions dispensed by retail network pharmacies	`PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies`	$165.78B	USD	Annual
Cash paid for inventory and prescriptions dispensed by retail network pharmacies	`PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies`	$189.77B	USD	Annual
Insurance benefits paid	`PaymentsForInsuranceBenefits`	$69.73B	USD	Annual
Insurance benefits paid	`PaymentsForInsuranceBenefits`	$63.60B	USD	Annual
Insurance benefits paid	`PaymentsForInsuranceBenefits`	$55.12B	USD	Annual
Cash paid to other suppliers and employees	`PaymentsToSuppliersAndEmployees`	$32.66B	USD	Annual
Cash paid to other suppliers and employees	`PaymentsToSuppliersAndEmployees`	$31.65B	USD	Annual
Cash paid to other suppliers and employees	`PaymentsToSuppliersAndEmployees`	$29.76B	USD	Annual
Interest and investment income received	`ProceedsFromInterestAndDividendsReceived`	$743.00M	USD	Annual
Interest and investment income received	`ProceedsFromInterestAndDividendsReceived`	$1.03B	USD	Annual
Interest and investment income received	`ProceedsFromInterestAndDividendsReceived`	$894.00M	USD	Annual
Interest paid	`InterestPaidNet`	$2.90B	USD	Annual
Interest paid	`InterestPaidNet`	$2.24B	USD	Annual
Interest paid	`InterestPaidNet`	$2.47B	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$3.19B	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$4.12B	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$2.93B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$15.87B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$16.18B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$18.27B	USD	Annual
Proceeds from sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$7.25B	USD	Annual
Proceeds from sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$6.47B	USD	Annual
Proceeds from sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$6.73B	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$9.96B	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$7.75B	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$9.64B	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.52B	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.73B	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.44B	USD	Annual
Proceeds from sale-leaseback transactions	`ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity`	-	USD	Annual
Proceeds from sale-leaseback transactions	`ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity`	-	USD	Annual
Proceeds from sale-leaseback transactions	`ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity`	$101.00M	USD	Annual
Acquisitions (net of cash acquired)	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$139.00M	USD	Annual
Acquisitions (net of cash acquired)	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$866.00M	USD	Annual
Acquisitions (net of cash acquired)	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$146.00M	USD	Annual
Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9)	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	$840.00M	USD	Annual
Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9)	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	$-1.25B	USD	Annual
Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9)	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	-	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-85.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-122.00M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-5.05B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-5.53B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-5.26B	USD	Annual
Proceeds from issuance of long-term debt	`ProceedsFromIssuanceOfLongTermDebt`	$987.00M	USD	Annual
Proceeds from issuance of long-term debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	Annual
Proceeds from issuance of long-term debt	`ProceedsFromIssuanceOfLongTermDebt`	$9.96B	USD	Annual
Repayments of long-term debt	`RepaymentsOfLongTermDebt`	$4.21B	USD	Annual
Repayments of long-term debt	`RepaymentsOfLongTermDebt`	$15.63B	USD	Annual
Repayments of long-term debt	`RepaymentsOfLongTermDebt`	$10.25B	USD	Annual
Derivative settlements	`PaymentsForDerivativeInstrumentFinancingActivities`	$7.00M	USD	Annual
Derivative settlements	`PaymentsForDerivativeInstrumentFinancingActivities`	$7.00M	USD	Point-in-time
Derivative settlements	`PaymentsForDerivativeInstrumentFinancingActivities`	-	USD	Annual
Derivative settlements	`PaymentsForDerivativeInstrumentFinancingActivities`	-	USD	Annual
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	$3.50B	USD	Annual
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	Annual
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	Annual
Dividends paid	`PaymentsOfDividends`	$2.91B	USD	Annual
Dividends paid	`PaymentsOfDividends`	$2.62B	USD	Annual
Dividends paid	`PaymentsOfDividends`	$2.62B	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$549.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$264.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$551.00M	USD	Annual
Payments for taxes related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$168.00M	USD	Annual
Payments for taxes related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$370.00M	USD	Annual
Payments for taxes related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$88.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$432.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$155.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-79.00M	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-7.70B	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-10.52B	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-11.36B	USD	Annual
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$614.00M	USD	Annual
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$2.63B	USD	Annual
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.65B	USD	Annual
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.69B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.41B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.04B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.30B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.69B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.41B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.04B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.30B	USD	Point-in-time
Net income	`ProfitLoss`	$7.99B	USD	Annual
Net income	`ProfitLoss`	$4.33B	USD	Annual
Net income	`ProfitLoss`	$7.19B	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$4.44B	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$4.49B	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$4.22B	USD	Annual
Loss on assets held for sale	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	Annual
Loss on assets held for sale	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	Annual
Loss on assets held for sale	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$2.53B	USD	Annual
Store impairments	`StoreImpairmentCharges`	-	USD	Annual
Store impairments	`StoreImpairmentCharges`	-	USD	Annual
Store impairments	`StoreImpairmentCharges`	$1.36B	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	$431.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$447.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$484.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$400.00M	USD	Annual
Gain on sale of subsidiaries	`GainLossOnSaleOfBusiness`	$269.00M	USD	Annual
Gain on sale of subsidiaries	`GainLossOnSaleOfBusiness`	-	USD	Annual
Gain on sale of subsidiaries	`GainLossOnSaleOfBusiness`	$475.00M	USD	Annual
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-363.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-89.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-766.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-1.44B	USD	Annual
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-674.00M	USD	Point-in-time
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on early extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-452.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-570.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-402.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-2.03B	USD	Annual
Other noncash items	`OtherNoncashIncomeExpense`	$-72.00M	USD	Annual
Other noncash items	`OtherNoncashIncomeExpense`	$-332.00M	USD	Annual
Other noncash items	`OtherNoncashIncomeExpense`	$390.00M	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$1.51B	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$2.97B	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$2.70B	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$1.44B	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$-735.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$973.00M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$30.00M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-364.00M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$491.00M	USD	Annual
Accounts payable and pharmacy claims and discounts payable	`IncreaseDecreaseInAccountsPayable`	$4.26B	USD	Annual
Accounts payable and pharmacy claims and discounts payable	`IncreaseDecreaseInAccountsPayable`	$2.90B	USD	Annual
Accounts payable and pharmacy claims and discounts payable	`IncreaseDecreaseInAccountsPayable`	$2.77B	USD	Annual
Health care costs payable and other insurance liabilities	`IncreaseDecreaseInInsuranceLiabilities`	$101.00M	USD	Annual
Health care costs payable and other insurance liabilities	`IncreaseDecreaseInInsuranceLiabilities`	$-231.00M	USD	Annual
Health care costs payable and other insurance liabilities	`IncreaseDecreaseInInsuranceLiabilities`	$992.00M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$2.74B	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$2.86B	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$6.46B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$15.87B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$16.18B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$18.27B	USD	Annual

Stockholders Equity 39 line items

Line Item	Tag	Value	Unit	Period
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Treasury shares held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Treasury shares held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$17.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$18.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$17.00M	USD	Point-in-time
Reduction to retained earnings as a result of new accounting standard adoption	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$69.70B	USD	Point-in-time
Reduction to retained earnings as a result of new accounting standard adoption	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$64.17B	USD	Point-in-time
Reduction to retained earnings as a result of new accounting standard adoption	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$74.84B	USD	Point-in-time
Reduction to retained earnings as a result of new accounting standard adoption	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$71.77B	USD	Point-in-time
Beginning of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$69.70B	USD	Point-in-time
Beginning of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$64.17B	USD	Point-in-time
Beginning of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$74.84B	USD	Point-in-time
Beginning of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$71.77B	USD	Point-in-time
Net income	`ProfitLoss`	$7.99B	USD	Annual
Net income	`ProfitLoss`	$4.33B	USD	Annual
Net income	`ProfitLoss`	$7.19B	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-314.00M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.60B	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$395.00M	USD	Annual
Stock option activity, stock awards and other	`StockIssuedDuringPeriodValueStockOptionsExercised`	$541.00M	USD	Annual
Stock option activity, stock awards and other	`StockIssuedDuringPeriodValueStockOptionsExercised`	$816.00M	USD	Annual
Stock option activity, stock awards and other	`StockIssuedDuringPeriodValueStockOptionsExercised`	$864.00M	USD	Annual
ESPP issuances, net of purchase of treasury shares	`ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod`	$57.00M	USD	Annual
ESPP issuances, net of purchase of treasury shares	`ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod`	$5.00M	USD	Annual
Purchase of treasury shares, net of ESPP issuances	`TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance`	$3.69B	USD	Annual
Common stock dividends	`DividendsCommonStock`	$2.91B	USD	Annual
Common stock dividends	`DividendsCommonStock`	$2.64B	USD	Annual
Common stock dividends	`DividendsCommonStock`	$2.64B	USD	Annual
Other increases (decreases) in noncontrolling interests	`NoncontrollingInterestOtherPeriodIncreaseDecrease`	$-7.00M	USD	Annual
Other increases (decreases) in noncontrolling interests	`NoncontrollingInterestOtherPeriodIncreaseDecrease`	$6.00M	USD	Annual
Other increases (decreases) in noncontrolling interests	`NoncontrollingInterestOtherPeriodIncreaseDecrease`	$-22.00M	USD	Annual
End of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$69.70B	USD	Point-in-time
End of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$64.17B	USD	Point-in-time
End of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$74.84B	USD	Point-in-time
End of year balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$71.77B	USD	Point-in-time

Comprehensive Income 30 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$7.99B	USD	Annual
Net income	`ProfitLoss`	$4.33B	USD	Annual
Net income	`ProfitLoss`	$7.19B	USD	Annual
Net unrealized investment gains (losses)	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$440.00M	USD	Annual
Net unrealized investment gains (losses)	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-2.32B	USD	Annual
Net unrealized investment gains (losses)	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-556.00M	USD	Annual
Change in discount rate on insurance reserves	`OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax`	$870.00M	USD	Annual
Change in discount rate on insurance reserves	`OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax`	-	USD	Annual
Change in discount rate on insurance reserves	`OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax`	$255.00M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$3.00M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	-	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-7.00M	USD	Annual
Net cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-26.00M	USD	Annual
Net cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-31.00M	USD	Annual
Net cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$17.00M	USD	Annual
Pension and other postretirement benefits	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$168.00M	USD	Annual
Pension and other postretirement benefits	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-20.00M	USD	Annual
Pension and other postretirement benefits	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$17.00M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-314.00M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.60B	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$395.00M	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$7.67B	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$7.59B	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$2.73B	USD	Annual
Comprehensive (income) loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-12.00M	USD	Annual
Comprehensive (income) loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$13.00M	USD	Annual
Comprehensive (income) loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$16.00M	USD	Annual
Comprehensive income attributable to CVS Health	`ComprehensiveIncomeNetOfTax`	$7.69B	USD	Annual
Comprehensive income attributable to CVS Health	`ComprehensiveIncomeNetOfTax`	$7.57B	USD	Annual
Comprehensive income attributable to CVS Health	`ComprehensiveIncomeNetOfTax`	$2.71B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.